- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02695992
Rate Control in Atrial Fibrillation II (RATAFII)
The RATAF II study is a randomized, prospective, parallel group study, designed to compare the effects of two different drug regimens for rate control in permanent AF (atrial fibrillation). We will investigate on the difference in effects on exercise capacity, biomarkers (NT-proBNP (N-terminal pro-brain natriuretic peptide), troponins, hs-CRP), heart rate, echocardiographic measurements and symptoms.
Our main hypothesis is that six months' treatment with the calcium channel blocker diltiazem will lower NT-proBNP and increase exercise capacity (peak VO2) compared to treatment with the beta blocker metoprolol in permanent AF.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Atrial fibrillation is a common cardiac disease, with increasing incidence and prevalence. There are two main treatment strategies for this arrhythmia, rhythm control and rate control. As rate control is easier to achieve and no major difference in outcome has been found between these two strategies, it is considered a reasonable initial treatment for the majority of AF patients.
Reduced exercise capacity is the most prevalent symptom in patients with permanent AF. In the first Rate control in Atrial Fibrillation (RATAF) study, we demonstrated that calcium channel blockers preserved exercise capacity, reduced arrhythmia-related symptoms and lowered levels of NT-proBNP - whereas the beta blockers reduced the exercise capacity, did not reduce arrhythmia-related symptoms and increased NT-proBNP.
These findings are relevant to a large proportion of patients with permanent AF, suggesting that calcium channel blockers should be the first drug of choice for rate control in patients without heart failure or coronary heart disease. Our results challenge the current widespread use of beta blockers in this setting. However, as the follow up time in the RATAF study was only 3 weeks, it is not clear if these effects are sustained over time. Furthermore, we do not know the mechanisms for the differential effects on exercise capacity, arrhythmia related symptoms and NT-proBNP levels.
In the RATAF II study we will investigate whether the effects on NT-proBNP levels, exercise capacity and symptoms are sustained over time, and explore potential mechanisms that may explain the difference in these effects. The study will provide new insights and results relevant for everyday clinical practice and be of importance for a large and growing group of patients.
A total of 240 patients will be included. Eligible patients will be recruited from the out-patient clinics at the participation hospitals and through advertisements in local newspapers. After inclusion and a wash-out period of 14 days free from drugs affecting the heart rate, patients will be examined by echocardiography, 12-lead ECG (electrocardiography), 24h Holter monitoring, maximal cardiopulmonary exercise test and venous blood sampling at rest, at maximal exercise and after recovery. Perceived arrhythmia related symptoms, quality of life and level of physical activity will be assessed using self-administered questionnaires.
Participants will be randomized through a computer-generated randomization list, to receive one of the study drug regimens; metoprolol 100 mg o.d. or diltiazem 360 mg o.d. The investigators and study personnel will be blinded with regard to allocated study drug. The participants themselves will know what study drug they are assigned. Also, study personnel not involved in examinations will also be able to acquire knowledge concerning assigned study drug, to ensure the process of dosage in the startup phase, assess adverse events (AE) and side effects throughout the study.
Examinations will be repeated after four weeks and six months. All examinations will be performed at the Department of Medical Research, Baerum Hospital to ensure standardized procedures.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Akershus
-
Rud, Akershus, Norway, 1309
- Vestre Viken Hospital Trust, Baerum Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Above 18 years of age
- Symptomatic, permanent AF of at least three months duration
- Resting heart rate ≥80 bpm
- Signed informed consent
Exclusion Criteria:
- Congestive heart failure
- Ischemic heart disease
- Hypotension (Systolic blood pressure <100 mmHg)
- Treatment with class I or III antiarrhythmic drugs
- Severe hepatic or renal failure
- Pregnancy or lactation
- Hypersensitivity or contradictions to study drugs
- Atrio-ventricular conduction disturbances
- Thyrotoxicosis
- Life limiting disease or substance abuse which may affect participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Metoprolol
Metoprolol, extended release tablets.
100 mg daily
|
Dosage 100 mg o.d.
Other Names:
|
Active Comparator: Diltiazem
Diltiazem, extended release tablets.
360 mg daily
|
Dosage 360 mg o.d.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of NT-proBNP
Time Frame: 4 weeks
|
Levels of NT-proBNP will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Levels of NT-proBNP
Time Frame: 6 months
|
Levels of NT-proBNP will be measured after 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exercise capacity defined as peak VO2
Time Frame: 4 weeks
|
Exercise capacity will be assessed by cardiopulmonary exercise test at baseline and after 4 weeks to assess change
|
4 weeks
|
Exercise capacity defined as peak VO2
Time Frame: 6 months
|
Exercise capacity will be assessed by cardiopulmonary exercise test after 6 months
|
6 months
|
Ventricular heart rate
Time Frame: 4 weeks
|
Ventricular heart rate will be assessed by ECG at rest and during exercise.
Will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Ventricular heart rate
Time Frame: 6 months
|
Ventricular heart rate will be assessed by ECG at rest and during exercise.
Will be measured after 6 months.
|
6 months
|
Other biomarkers
Time Frame: 4 weeks
|
Levels of other biomarkers such as hs-troponins, hs-CRP will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Other biomarkers
Time Frame: 6 months
|
Levels of other biomarkers such as hs-troponins, hs-CRP will be measured after 6 months.
|
6 months
|
Symptoms
Time Frame: 4 weeks
|
Symptoms will be assessed using a validated, self-administered questionnaire, the Symptom Checklist - Frequency and Severity (SCL).
This will be filled out at baseline and 4 weeks to assess change.
|
4 weeks
|
Symptoms
Time Frame: 6 months
|
Symptoms will be assessed using a validated, self-administered questionnaire, the Symptom Checklist - Frequency and Severity (SCL).
This will be filled out at 6 months.
|
6 months
|
Quality of life in SF-36
Time Frame: 4 weeks
|
The SF-36 (Short Form 36 Health Survey) questionnaire assessing quality of life will be filled out at baseline and 4 weeks to assess change.
|
4 weeks
|
Quality of life in SF-36
Time Frame: 6 months
|
The SF-36 questionnaire assessing quality of life will be filled out at 6 months.
|
6 months
|
Echocardiographic measures - Standard parasternal long axis and three apical views recordings.
Time Frame: 4 weeks
|
Will be done in the end expiratory phase with the subjects in supine lateral position.
Will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Echocardiographic measures - Standard parasternal long axis and three apical views recordings.
Time Frame: 6 months
|
Will be done in the end expiratory phase with the subjects in supine lateral position.
Measured at 6 months.
|
6 months
|
Echocardiographic measures - Left ventricular dimension, septal and posterior wall thickness.
Time Frame: 4 weeks
|
Will be measured as recommended by American Society of Echocardiography.
Will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Echocardiographic measures - Left ventricular dimension, septal and posterior wall thickness.
Time Frame: 6 months
|
Will be measured as recommended by American Society of Echocardiography.
Measured at 6 months.
|
6 months
|
Echocardiographic measures - Left ventricular mass.
Time Frame: 4 weeks
|
Will be measured as recommended by American Society of Echocardiography.
Will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Echocardiographic measures - Left ventricular mass.
Time Frame: 6 months
|
Will be measured as recommended by American Society of Echocardiography.
Measured at 6 months.
|
6 months
|
Echocardiographic measures - Left ventricular and left atrial maximal and minimal volumes.
Time Frame: 4 weeks
|
Will be calculated by 2D biplane and 4-chamber and 2D long axis views.
(ml/m2).
Will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Echocardiographic measures - Left ventricular and left atrial maximal and minimal volumes.
Time Frame: 6 months
|
Will be calculated by 2D biplane and 4-chamber and 2D long axis views.
(ml/m2).
Measured at 6 months.
|
6 months
|
Echocardiographic measures - Left ventricular ejection fraction will also be calculated.
Time Frame: 4 weeks
|
Using the modified Simpsons rule.
Will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Echocardiographic measures - Left ventricular ejection fraction will also be calculated.
Time Frame: 6 months
|
Using the modified Simpsons rule.
Measured at 6 months.
|
6 months
|
Echocardiographic measures - Transmitral flow and pulmonary venous flow.
Time Frame: 4 weeks
|
Will be assessed by pulsed Doppler.
Tissue Doppler imaging-derived indices will be recorded at the base of the septal and lateral mitral annulus.
(cm/s).
Will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Echocardiographic measures - Transmitral flow and pulmonary venous flow.
Time Frame: 6 months
|
Will be assessed by pulsed Doppler.
Tissue Doppler imaging-derived indices will be recorded at the base of the septal and lateral mitral annulus.
(cm/s).
Measured at 6 months.
|
6 months
|
Echocardiographic measures - Global and regional longitudinal left ventricular strain.
Time Frame: 4 weeks
|
Will be analysed by a semi-automated speckle tracking technique.
Will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Echocardiographic measures - Global and regional longitudinal left ventricular strain.
Time Frame: 6 months
|
Will be analysed by a semi-automated speckle tracking technique.Measured at 6 months.
|
6 months
|
Echocardiographic measures - Left atrial deformation for assessment of global as well as regional left atrial strain.
Time Frame: 4 weeks
|
Will be analysed by a semi-automated speckle tracking technique.
Characterizing both reservoir and conduit function.
Will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Echocardiographic measures - Left atrial deformation for assessment of global as well as regional left atrial strain.
Time Frame: 6 months
|
Will be analysed by a semi-automated speckle tracking technique.
Characterizing both reservoir and conduit function.
Measured at 6 months.
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood pressure
Time Frame: 4 weeks
|
Blood pressure will be measured at baseline and after 4 weeks to assess change
|
4 weeks
|
Blood pressure
Time Frame: 6 months
|
Blood pressure will be measured after 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sara Reinvik Ulimoen, MD PhD, Vestre Viken HF Baerum Hospital
Publications and helpful links
General Publications
- Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010 Apr 15;362(15):1363-73. doi: 10.1056/NEJMoa1001337. Epub 2010 Mar 15.
- European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29. No abstract available. Erratum In: Eur Heart J. 2011 May;32(9):1172.
- Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5. doi: 10.1001/jama.285.18.2370.
- Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J. 2014 Feb;35(8):517-24. doi: 10.1093/eurheartj/eht429. Epub 2013 Oct 17.
- Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol. 2013 Jan 15;111(2):225-30. doi: 10.1016/j.amjcard.2012.09.020. Epub 2012 Oct 27.
- Ulimoen SR, Enger S, Norseth J, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A. Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation. Clin Cardiol. 2014 Jul;37(7):422-7. doi: 10.1002/clc.22281. Epub 2014 Apr 3.
- Van Gelder IC, Hobbelt AH, Mulder BA, Rienstra M. Rate control in atrial fibrillation: many questions still unanswered. Circulation. 2015 Oct 27;132(17):1597-9. doi: 10.1161/CIRCULATIONAHA.115.018952. Epub 2015 Sep 17. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Biomarkers
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Heart Diseases
- Therapeutic Uses
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Calcium channel blockers
- Adrenergic beta-Antagonists
- Vasodilator Agents
- Sympatholytics
- Neurotransmitter Agents
- Metoprolol
- Cardiovascular Agents
- NT-proBNP
- Molecular Mechanisms of Pharmacological Action
- Adrenergic Agents
- Permanent atrial fibrillation
- Beta blockers
- Diltiazem
- Membrane Transport Modulators
- Adrenergic Antagonists
- Adrenergic beta-1 Receptor Antagonists
- Rate control in atrial fibrillation
- Management of atrial fibrillation
- Atrial fibrillation and biomarkers
- Arrhythmias, cardiac
- Pathological processes
- Troponins
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Arrhythmias, Cardiac
- Atrial Fibrillation
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Metoprolol
- Diltiazem
Other Study ID Numbers
- 240415
- 2015-001918-98 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Metoprolol
-
SanionaCompleted
-
University of CincinnatiTerminated
-
AstraZenecaCompletedAcute Myocardial Infarction
-
University of MinnesotaUniversity of Alabama at Birmingham; United States Department of DefenseTerminatedPulmonary Disease, Chronic ObstructiveUnited States
-
East Coast Institute for ResearchCompletedHypertension | Female Sexual DysfunctionUnited States
-
AstraZenecaSt. John's Research InstituteCompletedPrimary HypertensionIndia
-
Bright Future Pharmaceuticals Factory O/B Bright...Chinese University of Hong KongUnknown
-
Harbin Medical UniversityBeijing Chao Yang HospitalCompletedHeart Failure | Anterior Myocardial InfarctionChina
-
Janssen Research & Development, LLCWithdrawn
-
University of FloridaFood and Drug Administration (FDA)Completed